Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Older patients with AML benefit greatly from SGN-CD33 and HMA therapy combo

Dr Amir Fathi, Massachusetts General Hospital, Boston, USA

Older patients with AML benefit greatly from SGN-CD33 and HMA therapy combo ( Dr Amir Fathi, Massachusetts General Hospital, Boston, USA )

SGN-CD33A combined with HMA therapy produces high remission rates among older...

Dr Amir Fathi - Massachusetts General Hospital, Boston, USA

SGN-CD33A combined with HMA therapy produces high remission rates among older patients with AML ( Dr Amir Fathi - Massachusetts General Hospital, Boston, USA )

Improved survival in adult ALL

Dr Nina Toft - Rigshospitalet, Copenhagen, Denmark

Improved survival in adult ALL ( Dr Nina Toft - Rigshospitalet, Copenhagen, Denmark )

Multiple myeloma highlights from EHA 2016

Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Paul Richardson, Prof Philip...

Multiple myeloma highlights from EHA 2016 ( Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Paul Richardson, Prof Philip McCarthy )

An overview of MCL from EHA 2016

Professor Simon Rule and Professor Steven Le Gouill

An overview of MCL from EHA 2016 ( Professor Simon Rule and Professor Steven Le Gouill )

Checkpoint inhibitor therapy benefits advanced bladder cancer patients

Dr Arjun Vasant Balar - NYU Langone Medical Center, New York, USA

Checkpoint inhibitor therapy benefits advanced bladder cancer patients ( Dr Arjun Vasant Balar - NYU Langone Medical Center, New York, USA )

Daratumumab slows progression in refractory multiple myeloma

Prof Palumbo - University of Turin, Turin, Italy

$Daratumumab slows progression in refractory multiple myeloma ( Prof Palumbo - University of Turin, Turin, Italy )$

Recent developments in targeted therapies

Dr Stephen Nimer - University of Miami, Miami, USA

Recent developments in targeted therapies ( Dr Stephen Nimer - University of Miami, Miami, USA )

MyPathway guidance of targeted therapy based on molecular profiles

Dr John Hainsworth - Sarah Cannon Research Institute, Nashville, USA

MyPathway guidance of targeted therapy based on molecular profiles ( Dr John Hainsworth - Sarah Cannon Research Institute, Nashville, USA )

Subset of anaplastic glioma patients benefit from adjuvant chemo

Dr Martin van den Bent - Erasmus MC Cancer Center, Rotterdam, The Netherlands

Subset of anaplastic glioma patients benefit from adjuvant chemo ( Dr Martin van den Bent - Erasmus MC Cancer Center, Rotterdam, The Netherlands )

ASCO 2016: What is the optimal chemotherapy dosing regimen for prostate cancer?

Prof Charles Ryan and Prof Nick James

ASCO 2016: What is the optimal chemotherapy dosing regimen for prostate cancer? ( Prof Charles Ryan and Prof Nick James )

Advanced RET-rearranged NSCLC

Dr Takashi Seto and Dr Kiyotaka Yoh

Advanced RET-rearranged NSCLC ( Dr Takashi Seto and Dr Kiyotaka Yoh )

More from ecancer